September 13, 2017 – PASS Coalition Testifies Before Congress Regarding the Need for Innovative Sunscreen Products
Testimony of Michael Werner, JD Partner, Holland & KnightOn behalf of The Public Access to SunScreens (PASS) Coalition House Committee on Energy and Commerce Subcommittee on HealthSeptember 13, 2017 Good
September 13, 2017 – PASS Coalition Testifies Before Congress Regarding the Need for Innovative Sunscreen Products
Given the lack of new and innovative sunscreen ingredients in the United States, the PASS Coalition has worked tirelessly with Congress and the FDA to reform the OTC monograph system
FDA’s Final Guidance Regarding Over-the-Counter Sunscreen Safety and Effectiveness Continues to Fall Short While Two Year Anniversary of Sunscreen Innovation Act Becoming Law Looms
For Immediate Release: November 22, 2016 Contact: Aimee Steel Lubin, aimee.lubin@hklaw.com / 202-828-1895 (Washington, D.C.) – Today the Food and Drug Administration (FDA) published “Nonprescription Sunscreen Drug Products — Safety
Comment from Public Access to Sun Screens Coalition
February 22, 2016 Kristen Hardin Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 22, Rm. 5443 Silver Spring, MD 20993-0002 RE: Public Comments
Comment from Public Access to Sun Screens Coalition
February 22, 2016 Kristen Hardin Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 22, Rm. 5443 Silver Spring, MD 20993-0002 RE: Public Comments
FDA’s Final Guidance Regarding Over-the-Counter Sunscreen Safety and Effectiveness Continues to Fall Short While Two Year Anniversary of Sunscreen Innovation Act Becoming Law Looms
For Immediate Release: November 22, 2016 Contact: Aimee Steel Lubin, aimee.lubin@hklaw.com / 202-828-1895 (Washington, D.C.) – Today the Food and Drug Administration (FDA) published “Nonprescription Sunscreen Drug Products — Safety
PASS Coalition Submits Comments in Response to FDA’s Draft Guidance on OTC Sunscreens’ Safety and Effectiveness
For Immediate Release: February 22, 2016 Contact: Aimee Steel Lubin, aimee.lubin@hklaw.com / 202-828-1895 (Washington, D.C.) — The Public Access to SunScreens (PASS) Coalition submitted comments in response to the FDA’s
PASS Coalition Commends Dr. Robert Califf for His Commitment to Work to Ensure New Sunscreens Get to Market
On the Brink of Year Anniversary of the Sunscreen Innovation Act Becoming Law, Nothing Has Changed Except Rising Melanoma Rates (Washington, D.C.) —The Public Access to SunScreens (PASS) Coalition
FDA’s Announcement on Ecamsule and Enzacamene Applications Demonstrates Clear Disregard for Increased Rates of Melanoma, Public’s Demand for Latest Sunscreen Technology.
Like the Six previously Pending Ingredients Ecamsule and Enzacamene Will Continue to be Held Hostage by the FDA Today, the Public Access to SunScreens (PASS) Coalition released a statement regarding
FDA’s Announcement on Ecamsule and Enzacamene Applications Demonstrates Clear Disregard for Increased Rates of Melanoma, Public’s Demand for Latest Sunscreen Technology.
Like the Six previously Pending Ingredients Ecamsule and Enzacamene Will Continue to be Held Hostage by the FDA Today, the Public Access to SunScreens (PASS) Coalition released a statement regarding